The Technical Analyst
Omega Therapeutics, Inc. [OMGA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Omega Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.09% $2.34
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 129.06 mill |
| EPS: | -1.800 |
| P/E: | -1.300 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 55.16 mill |
| Avg Daily Volume: | 0.461 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.22x |
| Company: PE -1.300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.05 - 2.63 ( +/- 12.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-07 | Mccauley Thomas | Buy | 125 000 | Stock Option (Right to Buy) |
| 2024-02-07 | Mccauley Thomas | Buy | 75 000 | Stock Option (Right to Buy) |
| 2024-02-07 | Karande Mahesh | Buy | 314 326 | Stock Option (Right to Buy) |
| 2024-02-07 | Karande Mahesh | Buy | 209 551 | Stock Option (Right to Buy) |
| 2024-02-07 | Moore Yan | Buy | 110 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 98.70 |
| Last 90 transactions |
| Buy: 34 429 434 | Sell: 15 655 033 |
Forecast:
16:00 - $2.35
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.35
Forecast 2: 16:00 - $2.35
Forecast 3: 16:00 - $2.35
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.34 (-2.09% ) |
| Volume | 0.302 mill |
| Avg. Vol. | 0.461 mill |
| % of Avg. Vol | 65.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OMGA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.57 | N/A | Active |
|---|
OMGA
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-23 07:00:00 - Press Release
Omega Therapeutics To Present New Preclinical Data On Epigenomic Upregulation At The American Society Of Gene And Cell Therapy 27th Annual Meeting
Cambridge, mass., april 23, 2024 (globe newswire) -- omega therapeutics, inc. (nasdaq: omga) (“omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mrna medicines, today announced it will present a poster at the american society of gene and cell therapy (asgct) 27th annual meeting taking place in baltimore, md, may 7 – 11, 2024. the poster will feature new preclinical data that demonstrate the ability of omega's programmable epigenomic controllers (ecs) to pre-transcriptionally upregulate gene expression across a diverse set of genes, offering a broad range of potential therapeutic applications.
2024-04-09 07:00:00 - Press Release
Omega Therapeutics Presents New Preclinical Data At Aacr 2024 Supporting The Potential Of Precision Epigenomic Control
Cambridge, mass., april 09, 2024 (globe newswire) -- omega therapeutics, inc. (nasdaq: omga) (“omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mrna medicines, today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a myc-targeting epigenomic controller (myc-ec) in models of egfr inhibitor (egfri)-resistant non-small cell lung cancer (nsclc) at the american association for cancer research annual meeting 2024, taking place in san diego, california, april 5 – 10. the company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage ec candidate, otx-2002.
2024-03-28 09:15:00 - Press Release
Omega Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Strategic Update
Cambridge, mass., march 28, 2024 (globe newswire) -- omega therapeutics, inc. (nasdaq: omga) (“omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mrna medicines, today announced financial results for the fourth quarter and full year ended december 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.
2024-03-06 07:00:00 - Press Release
Omega Therapeutics Announces Two Poster Presentations At The American Association For Cancer Research Annual Meeting 2024
Cambridge, mass., march 06, 2024 (globe newswire) -- omega therapeutics, inc. (nasdaq: omga) (“omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mrna medicines, today announced that it will present two posters at the american association for cancer research (aacr) annual meeting 2024, taking place in san diego, california, april 5 – 10, 2024. the first poster will feature preclinical data validating a novel method for evaluating epigenomic controller (ec) target engagement using noninvasive liquid biopsies. additionally, the company will present new preclinical data supporting a myc-targeting ec approach in models of non-small cell lung cancer (nsclc) resistant to egfr inhibitors.
2024-01-04 05:59:00 - Press Release
Novo Nordisk Enters Into Research Collaborations With Omega Therapeutics And Cellarity On Novel Treatment Approaches For Cardiometabolic Diseases
BagsvÆrd, denmark, cambridge, mass., and somerville, mass. 4 january, 2024 – novo nordisk, omega therapeutics, inc. (nasdaq: omga) (“omega”) and cellarity inc. today announced that novo nordisk has entered into separate research collaborations with each company. the omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. the cellarity collaboration aims to unravel novel biological drivers of mash and will leverage cellarity's platform to develop a small molecule therapy against this disease.
Latest News
2024-04-17 10:55:25 - Zacks Investment Research
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-04-03 13:00:17 - Zacks Investment Research
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know
Omega Therapeutics (OMGA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-31 06:22:14 - Seeking Alpha
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung cancer, and obesity. Omega Therapeutics has signed a collaboration with Novo Nordisk to develop a drug for obesity management, validating the potential of its platform.
2024-03-28 11:26:08 - Zacks Investment Research
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.64 per share a year ago.
2024-01-16 14:10:03 - Seeking Alpha
Omega Therapeutics: The Next Weight Loss Drug Runner
Demand for weight loss drugs and related stocks is high, with companies like Novo Nordisk and Eli Lilly experiencing significant returns. Omega Therapeutics may be a speculative investment opportunity in the weight loss drug market as it recently entered into a collaboration with Novo Nordisk. While initially spiking, OMGA's reaction to news of this collaboration has been relatively muted compared to NVO.
2024-01-09 23:01:39 - InvestorPlace
The 3 Best Biotech Stocks to Buy in January 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.
2024-01-05 14:17:14 - Zacks Investment Research
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.
2024-01-04 08:20:23 - InvestorPlace
Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?
Omega Therapeutics (NASDAQ: OMGA ) stock is rising higher on Thursday after the company announced a research collaboration agreement with Novo Nordisk (NYSE: NVO ). The collaboration between the two companies will focus on developing an obesity management treatment.
2024-01-02 16:05:00 - GlobeNewsWire
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 9:45 a.m. PT (12:45 p.m. ET).
2023-12-04 16:00:00 - GlobeNewsWire
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET.